Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Series A leads to €5mm for two-year-old Complix NV; €2mm added

Executive Summary

Complix NV (developing a new class of therapeutics for autoimmune and infectious diseases) has raised €5mm ($6.1mm) in its Series A financing co-led by Vesalius Biocapital and LRM. Also participating in the round were returning shareholders, company management, and public research institute CRP-Santé, which is collaborating with Complix on antiviral therapies.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies